A Phase 3b, Multi-center, Open-label, Trial to Evaluate the Long Term Safety of Titrated Immediate -release Tolvaptan (OPC 41061,30mg to 120mg/day, Split-dose) in Subjects with Autosomal Dominant Polycystic Kidney Disease
The Department of Medicine’s Division of General Internal
Medicine had a strong showing at the 2017 Society of General
Internal Medicine (SGIM) annual meeting with 11 research posters
and one oral presentation.
Researchers at the Hunter James Kelly Research Institute at the
University at Buffalo report on research that illuminates what
causes some kinds of neuropathy and may reveal potentially powerful